ATTANA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.082 SEK | -1.20% |
|
+15.49% | -17.17% |
| Feb. 22 | Attana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Attana Lands Order for Kinetic Interaction Analysis of Tissue in US | MT |
| Sales 2021 | 8.48M 779K | Sales 2022 | 13.11M 1.2M | Capitalization | 41.6M 3.82M |
|---|---|---|---|---|---|
| Net income 2021 | -16M -1.47M | Net income 2022 | -14M -1.29M | EV / Sales 2021 | 17.5 x |
| Net cash position 2021 | 10.77M 990K | Net Debt 2022 | 3.24M 298K | EV / Sales 2022 | 3.42 x |
| P/E ratio 2021 |
-9.33
x | P/E ratio 2022 |
-2.84
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.20% | ||
| 1 week | +15.49% | ||
| Current month | +38.98% | ||
| 1 month | +34.43% | ||
| 3 months | -9.89% | ||
| 6 months | -62.56% | ||
| Current year | -17.17% |
1 week
0.07
0.08
1 month
0.060.08
Current year
0.060.12
1 year
0.060.32
3 years
0.061.97
5 years
0.062.40
10 years
0.062.40
| Managers | Title | Age | Since |
|---|---|---|---|
Marcus Söderberg
CEO | Chief Executive Officer | - | 23-09-17 |
| Founder | 54 | 01-12-31 | |
Anders Ulrikson
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 16-12-31 | |
Arne Nabseth
CHM | Chairman | 61 | 15-09-30 |
| Founder | 54 | 01-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.082 | -1.20% | 179,286 |
| 24-04-23 | 0.083 | +10.67% | 263,830 |
| 24-04-22 | 0.075 | +15.38% | 265,434 |
| 24-04-19 | 0.065 | -5.80% | 448,486 |
| 24-04-18 | 0.069 | -1.43% | 95,113 |
End-of-day quote NORDIC GROWTH MARKET, April 23, 2024
More quotes
Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality control the production line of a biological pharmaceutical or gain insight into advanced dynamic features of target molecules, as well as by academic institutions within the life sciences. Attanaâs biosensors are used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.17% | 2.97M | |
| -26.68% | 961M | |
| -18.52% | 131M | |
| +7.32% | 63.05M | |
| -15.34% | 61.84M | |
| +1.20% | 50.36M |
- Stock Market
- Equities
- ATANA Stock
